
Synthetic Data for Rare Subgroups – A Decision-Grade Tool to Inform Drug Development
In drug development, access to diverse and representative patient data is often a limiting factor, especially when studying rare subgroups. This is where synthetic data can offer powerful, practical value. At InSilicoTrials, we use synthetic data not as a replacement